Moïse Desvarieux1, Franck Boccara, Jean-Luc Meynard, Jean-Phillipe Bastard, Ziad Mallat, Beny Charbit, Ryan T Demmer, Nabila Haddour, Soraya Fellahi, Alain Tedgui, Ariel Cohen, Jacqueline Capeau, Anders Boyd, Pierre-Marie Girard. 1. aDepartment of Epidemiology, Columbia University, Mailman School of Public Health, New York, USA bInserm U-738 and École des Hautes Études en Santé Publique cAP-HP Department of Cardiology, Hôpital Saint-Antoine, F-75012, Paris, France dUPMC Univ Paris 06, Paris F75012 eAPHP Department of Infectious and Tropical Diseases, Hôpital Saint-Antoine fAPHP Hôpital Tenon, Service de biochimie et hormonologie, Paris F75020 gInserm UMR_S938, Paris F-75012 hInserm U970, Paris-Cardiovascular Research Center, and Paris-Descartes University iAP-HP Centre d'Investigation Clinique Paris-EST (9304), Hôpital Pitié-Salpêtrière, Paris, France jDepartment of Medicine, University of Cambridge, Cambridge, UK kInserm UMR-S707, Paris, France.
Abstract
OBJECTIVES: To determine whether the reported increased atherosclerotic risk among HIV-infected individuals is related to antiretroviral therapy (ART) or HIV infection, whether this risk persists in never-smokers, and whether inflammatory profiles are associated with higher risk. DESIGN: Matched cross-sectional study. METHODS: A total of 100 HIV-infected patients (50 ART-treated >4 years, 50 ART-naive but HIV-infected >2 years) and 50 HIV-negative controls were recruited in age-matched never-smoking male triads (mean age 40.2 years). Carotid intima-media maximal thickness (c-IMT) was measured across 12 sites. Pro-inflammatory [highly sensitive C-reactive protein (hs-CRP), resistin, interleukin-6, interleukin-18, insulin, serum amyloid A, D-dimer) and anti-inflammatory (total and high molecular weight adiponectin, interleukin-27, interleukin-10) markers were dichotomized into high/low scores (based on median values). c-IMT was compared across HIV/treatment groups or inflammatory profiles using linear regression models adjusted for age, diabetes, hypertension, and, for HIV-infected patients, nadir CD4 cell counts. RESULTS: Although adjusted c-IMT initially tended to be thicker in ART-exposed patients (P=0.2), in post-hoc analyses stratifying by median HIV duration we observed significantly higher adjusted c-IMT in patients with longer (>7.9 years: 0.760±0.008 mm) versus shorter prevalent duration of known HIV infection (<7.9 years: 0.731±0.008 mm, P=0.02), which remained significant after additionally adjusting for ART (P=0.04). Individuals with low anti-inflammatory profile (<median versus >median score) had thicker c-IMT (0.754±0.006mm versus 0.722±0.006 mm, P<0.001), with anti-inflammatory markers declining as prevalent duration of HIV infection increased (P for linear trend <0.001). CONCLUSION: Known HIV duration is related to thicker c-IMT, irrespective of ART, in these carefully selected age-matched never-smoking HIV-treated and ART-naive male individuals. Higher levels of anti-inflammatory markers appeared protective for atherosclerosis.
OBJECTIVES: To determine whether the reported increased atherosclerotic risk among HIV-infected individuals is related to antiretroviral therapy (ART) or HIV infection, whether this risk persists in never-smokers, and whether inflammatory profiles are associated with higher risk. DESIGN: Matched cross-sectional study. METHODS: A total of 100 HIV-infectedpatients (50 ART-treated >4 years, 50 ART-naive but HIV-infected >2 years) and 50 HIV-negative controls were recruited in age-matched never-smoking male triads (mean age 40.2 years). Carotid intima-media maximal thickness (c-IMT) was measured across 12 sites. Pro-inflammatory [highly sensitive C-reactive protein (hs-CRP), resistin, interleukin-6, interleukin-18, insulin, serum amyloid A, D-dimer) and anti-inflammatory (total and high molecular weight adiponectin, interleukin-27, interleukin-10) markers were dichotomized into high/low scores (based on median values). c-IMT was compared across HIV/treatment groups or inflammatory profiles using linear regression models adjusted for age, diabetes, hypertension, and, for HIV-infectedpatients, nadir CD4 cell counts. RESULTS: Although adjusted c-IMT initially tended to be thicker in ART-exposed patients (P=0.2), in post-hoc analyses stratifying by median HIV duration we observed significantly higher adjusted c-IMT in patients with longer (>7.9 years: 0.760±0.008 mm) versus shorter prevalent duration of known HIV infection (<7.9 years: 0.731±0.008 mm, P=0.02), which remained significant after additionally adjusting for ART (P=0.04). Individuals with low anti-inflammatory profile (<median versus >median score) had thicker c-IMT (0.754±0.006mm versus 0.722±0.006 mm, P<0.001), with anti-inflammatory markers declining as prevalent duration of HIV infection increased (P for linear trend <0.001). CONCLUSION: Known HIV duration is related to thicker c-IMT, irrespective of ART, in these carefully selected age-matched never-smoking HIV-treated and ART-naive male individuals. Higher levels of anti-inflammatory markers appeared protective for atherosclerosis.
Authors: Khaled Z Abd-Elmoniem; Aylin B Unsal; Sarah Eshera; Jatin R Matta; Nancy Muldoon; Dorothea McAreavey; Julia B Purdy; Rohan Hazra; Colleen Hadigan; Ahmed M Gharib Journal: Clin Infect Dis Date: 2014-08-25 Impact factor: 9.079
Authors: Lindsay T Fourman; Charles F Saylor; Lediya Cheru; Kathleen Fitch; Sara Looby; Kiana Keller; Jake A Robinson; Udo Hoffmann; Michael T Lu; Tricia Burdo; Janet Lo Journal: J Infect Dis Date: 2020-02-03 Impact factor: 5.226
Authors: Lucas Jennelle; Ruth Hunegnaw; Larisa Dubrovsky; Tatiana Pushkarsky; Michael L Fitzgerald; Dmitri Sviridov; Anastas Popratiloff; Beda Brichacek; Michael Bukrinsky Journal: J Biol Chem Date: 2014-08-28 Impact factor: 5.157
Authors: Beda Brichacek; Christina Darwish; Anastas Popratiloff; Larisa Dubrovsky; Michael Bukrinsky Journal: AIDS Res Hum Retroviruses Date: 2014-09-08 Impact factor: 2.205